CDKN1A and prostate carcinoma: RP11-462C24.1, RP1-13P20.6, Prostate cancer-associated ncRNA transcripts 1, promoter of CDKN1A antisense DNA damage activated RNA (PANDAR), and non-coding RNA expressed in aggressive neuroblastoma were identified as the potential novel prognostic markers for CRC [114–118].